Can a dose increase control lung cancer that Isn't shrinking?
NCT ID NCT07298148
First seen Jan 06, 2026 · Last updated May 22, 2026 · Updated 24 times
Summary
This study tests whether a higher dose (160 mg) of the drug firmonertinib can improve outcomes for people with advanced EGFR-mutant non-small cell lung cancer whose tumors have stayed stable but not shrunk after 8 weeks on the standard 80 mg dose. About 28 adults aged 18-75 with no prior treatment will take the higher dose daily. The main goal is to see if more tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.